ACTUATE THERAPEUTICS, INC. Segments Disclosure
14. SEGMENT REPORTING
The Company manages its operations as a single operating segment. which includes all activities related to the development and potential commercialization of novel therapies for the treatment of cancer, for the purposes of assessing performance and making operating decisions. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company’s chief operating decision maker (“CODM”). The Company’s CODM is its President and Chief Executive Officer, who reviews and evaluates consolidated net income (loss) for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.
In addition to the significant expense categories included within consolidated net income (loss) presented on the Company’s Consolidated Statements of Operations, see below for disaggregated amounts that comprise research and development expenses for the years ended December 31, 2024 and 2023:
| Year Ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| External clinical trial expenses | $ | 13,412,743 | $ | 13,986,355 | ||||
| Personnel and consulting expenses | 3,158,993 | 3,675,373 | ||||||
| CMC related costs | 1,707,132 | 2,246,280 | ||||||
| Preclinical and biomarker research | 397,408 | 1,800,324 | ||||||
| Total research and development expenses | $ | 18,676,276 | $ | 21,708,332 | ||||
In addition, the Company has a wholly-owned subsidiary, Actuate Therapeutics Limited, which is a dormant entity with no assets, liabilities or operations in any foreign countries.
Want the next ACTUATE THERAPEUTICS, INC. segments disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment ACTUATE THERAPEUTICS, INC.'s next filing hits EDGAR. No credit card, your email never gets sold.
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.